Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. has demonstrated promising advancements in its clinical development of fibroblast-based therapies, particularly for diabetic foot ulcers, indicating potential for improved wound healing quality through enhanced re-epithelialization and cell proliferation. Additionally, the company has shown positive preclinical results in reducing tumor size using bone marrow organoid transplants, suggesting a scalable option for future cancer treatment applications. The recent positive updates related to IND-enabling processes for fibroblast spheroids further bolster the company's position in the market for chronic-relapse psoriasis and other serious conditions, supporting a positive outlook for its stock performance.

Bears say

FibroBiologics faces several significant risks that contribute to a negative outlook on its stock. The company's developmental candidates may not meet peak commercial revenue estimates, which could be impacted by their market size, penetration rates, and pricing strategies. Additionally, there is a concerning risk regarding the inability to secure adequate capital resources to sustain operations and continue program development and commercialization efforts.

Fibrobiologics Inc (FBLG) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.